Cardinal Health · CAH

Cardinal Health's higher pharma profit range mostly carries forward one strong quarter in drug distribution

Pharma profit beat management's own August signal in the first quarter, and the higher full-year range passes that through while assuming slower growth for the rest of the year.

3 min read Published on

Published by

Inve Content team

Cardinal Health stock page → More news from Nov 11, 2026

Temperature-controlled medicine totes move along stainless-steel conveyors inside an automated pharmaceutical warehouse.
Illustration Photo: Inve Research Desk

Cardinal Health raised its full-year profit range for drug distribution after that business had a far stronger first quarter than management had signalled. Profit in the pharmaceutical and specialty segment rose 17% to $783 million in the September 2026 quarter. In August, management had said growth in that quarter would come in near the high end of its full-year range of 8% to 11%.

That segment is the core of the company, which buys medicines from drugmakers and distributes them to pharmacies, hospitals and clinics, alongside smaller businesses making medical products and serving patients at home. The company credited brand-name and specialty drugs and its generics programme for last quarter's gain. Part of the specialty growth came from Solaris, an acquisition in services for specialist doctors' practices, which stops adding to year-on-year growth once the company has owned it for a full year, during the second quarter.

The company has now lifted its full-year pharma profit range to 10% to 12%. Measured against the top of the August range, the first quarter came in about $43 million ahead of the signal, calculated from the reported quarters. Moving the range's midpoint up adds about $42 million to the year on last year's pharma profit. In other words, the raise is close to the first quarter's surprise carried into the annual figure, with little extra assumed for the remaining months.

The raised range asks for about 9% pharma profit growth in the last three quarters, after 17% in the first

%

  1. First quarter, actual 17.4%
  2. August steer for the first quarter, top of range 11%
  3. Remaining three quarters, implied at the new midpoint 8.99%
Remaining-quarter growth is calculated from the reported quarterly pharma profit and the midpoint of the new 10% to 12% range.

Calculated from the same figures, the new range implies pharma profit growth of roughly 8% to 10% across the second, third and fourth quarters combined. Management does not present that as weaker demand. The chief financial officer, Aaron Alt, said that "following strong growth in the first quarter, we expect earnings growth to moderate in the second and third quarters", with a pickup in the fourth, and attributed the pattern mostly to the timing of customer renewals and to lapping Solaris.

Last quarter's pharma profit came within $1 million of fiscal 2026's best quarter; year-ago bases are uneven

$m

Pharma segment profit by quarter

  1. $667M Q1 FY26
  2. $687M Q2 FY26
  3. $784M Q3 FY26
  4. $645M Q4 FY26
  5. $783M Q1 FY27
Pharmaceutical and Specialty Solutions segment profit; fiscal years end in June.

The largest of those renewals has just been agreed. The company signed a binding letter of intent to renew its distribution agreements with CVS Health, which chief executive Jason Hollar described as its largest customer, with the renewal running to June 2032. Alt said the original guidance had largely allowed for its financial effect, so the contract accounts for little of the raise.

Last year's record is context for reading the range, though not a forecast of it. The company first set fiscal 2026 adjusted EPS guidance at an investor day, raised it at all four quarterly calls of the year, each time above the guide before it, and finished above the top of that final range once a tariff refund is excluded. It has now raised this year's adjusted EPS range to $12.80 to $13.00 a share from $12.40 to $12.60. Pharma is only part of that: the company also raised its profit growth range for the Other businesses and lowered its tax-rate and share-count assumptions.

Adjusted EPS also grew faster last quarter than the full-year guidance implies for the year as a whole. Besides the pharma timing, the company said a lower share count and a lower tax rate contributed to the quarter alongside higher operating earnings.

The one segment moving the other way is medical products, where profit fell to $33 million. Management kept its range of $200 million to $220 million for that segment's profit this year but said high petroleum costs linked to the Iran conflict are pushing it toward the low end; in August it had described that outcome only as a risk if the conflict dragged on. Medical products is small beside pharma, so the year still turns on whether pharma growth slows as management has laid out.

Cardinal Health stock page →

The record: full financial tables

Financials

Income statement, last 8 quarters

$ million; YoY and margin in %
Quarter endSalesYoYOperating profitOp. marginPBTNet profit
Sep 202667,513+5.5%7531.1%688554
Dec 202565,627+18.8%7071.1%630467
Sep 202564,009+22.4%6681.0%598450
Jun 202560,159+0.5%4280.7%384239
Mar 202554,8780.0%7301.3%665506
Dec 202455,264−3.8%5491.0%511400
Sep 202452,277−4.3%5681.1%541416
Jun 202459,867+12.0%4010.7%391235

Balance sheet

$ million
As ofEquityDebtCashFixed assetsTotal assets
Sep 2026−3,0256,9295,2642,99959,544
Jun 2026−2,8837,0044,8563,03157,299
Dec 2025−2,8848,3472,7772,87758,083
Sep 2025−2,8798,9804,5932,83155,228

Cash flow

$ million
Year endOperatingInvestingFinancingFree cash flow
Jun 20265,174−2,584−1,6024,525
Jun 20252,397−5,5931,9401,850
Jun 20243,762−1,849−8473,251
Jun 20232,844−454−3,0512,363